Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers.
2025 · 2nd Quarter (Apr 1 - June 30)
BIOWOUND SOLUTIONS
Filed by THE MCMANUS GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Aug 4, 2025
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- THE MCMANUS GROUP
- Client
- BIOWOUND SOLUTIONS
- Filing UUID
- 33fb03af-a5e8-409f-92f1-63317ba31fc6
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.